Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography

Cardiology

Volumn 109, Issue 3, 2008, Pages 196-201

  Rondina, Matthew T ^a   Lappé, Jason M ^b   Carlquist, John F ^a,b   Muhlestein, Joseph B ^a,b   Kolek, Matthew J ^b   Horne, Benjamin D ^b   Pearson, Robert R ^b   Anderson, Jeffrey L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b LDS HOSPITAL   (United States)

Author keywords

C reactive protein; Cardiovascular risk; Coronary artery disease; Inflammation; Soluble CD40 ligand

Indexed keywords

CD40 LIGAND;

ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CATHETERIZATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX RATIO; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 38949109406     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106683     Document Type: Article

References (22)

1. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-67.
2. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL 3rd, Goldberg RJ, Michelson AD: Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-1006.
3. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA: Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-1316.
4. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-203.
5. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
6. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA: The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by co-expressed CD40. Blood 2001;98:1047-1054.
7. Lee Y, Lee WH, Lee SC, Ahn KJ, Choi YH, Park SW, Seo JD, Park JE: CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999;92:11-16.
8. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-399.
9. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S: Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest 2001;108:1451-1458.
10. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111.
11. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Gullestad L: Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-620.
12. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U: Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108:1049-1052.
13. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM: Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-2268.
14. Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. N Engl J Med 1984;310:750-758.
15. Clarke JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, Kolek MJ, Mower CP, Crane AM, Roberts WL, Muhlestein JB: Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol 2005;95:155-158.
16. Tanne D, Haim M, Goldbourt U, Boyko V, Reshef T, Adler Y, Benderly M, Mekori YA, Behar S: CD40 ligand and risk of ischemic stroke or coronary events in patients with chronic coronary heart disease. Int J Cardiol 2006;107:322-326.
17. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA: Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.
18. Topol EJ, Serruys PW: Frontiers in interventional cardiology. Circulation 1998;98:1802-1820.
19. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI: Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
20. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I: Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-2171.
21. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A: Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996;94:1239-1246.
22. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, Fazia M, Iezzi A, Cuccurullo C, Pini B, Bucci M, Santucci A, Cuccurullo F, Mezzetti A: Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003;108:2776-2782.